Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri System
    • Missouri Summits
    • Missouri Regional Life Sciences Summit 2010
    • Abstracts (Missouri Regional Life Sciences Summit 2010)
    • View Item
    •   MOspace Home
    • University of Missouri System
    • Missouri Summits
    • Missouri Regional Life Sciences Summit 2010
    • Abstracts (Missouri Regional Life Sciences Summit 2010)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Inhibition Mechanism of EFdA, a Highly Potent Inhibitor of HIV Reverse Transcriptase [abstract]

    Michailidis, Eleftherios
    Marchand, Bruno
    Kodama, Eiichi N.
    Singh, Kamlendra
    Kirby, Karen, 1979-
    Ong, Yee T.
    Ryan, Emily M.
    Nagy, Eva
    Ashida, Noriyuki
    Murphey-Corb, Mickey
    Mitsuya, Hiroaki
    Parniak, Michael A.
    Sarafianos, Stefan G.
    View/Open
    [PDF] InhibitionMechanismEFdA[abstract].pdf (17.33Kb)
    Date
    2010-02
    Contributor
    University of Missouri (System)
    Format
    Abstract
    Metadata
    [+] Show full item record
    Abstract
    The nucleoside 4'-ethynyl-2-fluoro-deoxyadenosine (EFdA) is one of the most potent antiretroviral nucleosides yet described, inhibiting replication of wild-type and multidrug-resistant HIV-1 strains in vitro (PBMC cells) with an EC50 as low as 50 pM. Our laboratory works in collaboration with academic, government and pharmaceutical industry laboratories, to characterize the mechanism of action of EFdA, and help develop it as a therapeutic for the treatment of HIV-infected patients, and as a topical microbicide to minimize sexual transmission of HIV. We have recently shown that the potency of antiviral activity stems in part from a mechanism of action not shown by any of the clinically used nucleoside antiretrovirals. Unlike other Reverse Transcriptase (RT) inhibitors, EFdA has a 3'-OH group which is necessary for nucleotide incorporation, yet it acts as a chain-terminator of retroviral DNA synthesis. Using biochemical techniques, we have determined that EFdA is incorporated very efficiently into the nascant viral DNA chain and blocks the incorporation of incoming nucleotides by stopping the translocation/movement of RT. Therefore, we have dubbed EFdA as a Translocation-Defective RT Inhibitor (TDRTI). A pilot collaborative study spearheaded by collaborators Parniak and Corb demonstrated that EFdA treatment of Rhesus Macaques resulted in a 2-3 log decrease in simian immunodeficiency virus (SIV) within seven days; these levels declined to undetectable levels (5-log reduction) within 2 months and essentially remained so for the duration of therapy. Hence, EFdA is a highly potent HIV RT inhibitor with in vitro and in vivo antiviral activities that warrant further development of the compound as a potential therapeutic for individuals harboring wild-type and/or multi-drug resistant HIV-1.
    URI
    http://hdl.handle.net/10355/6194
    Part of
    Abstracts (Missouri Regional Life Sciences Summit 2010)
    Collections
    • Abstracts (Missouri Regional Life Sciences Summit 2010)
    • Molecular Microbiology and Immunology presentations (MU)

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems